To the Editor In their article, Margonis et al1 report the role of BRAF V600E mutation as the strongest determinant of prognosis in a large cohort of 849 patients with resected colorectal liver metastases (CRLM). Their findings are consistent with previous reports in the literature,2 including our retrospective series.3
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Moretto R, Cremolini C, Falcone A. BRAF V600E Mutation as a Negative Prognostic Determinant in Resected Colorectal Liver Metastases. JAMA Surg. 2018;153(12):1162–1163. doi:10.1001/jamasurg.2018.3334
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: